Showing posts with label News. Show all posts
Showing posts with label News. Show all posts

Friday, October 14, 2011

Are you planning to prescribe alpha-blocker to your patient?Check this out, first! AAFP 2008


Ophthalmologists Reach Out to FPs


Consider Cataracts Before Prescribing Alpha Blockers for Your Patients

jump to the site
By Paula Haas
Posted: 7/2/2008, 2:40 p.m. -- If you're about to prescribe an alpha blocker for an older adult with hypertension or a prostate or urinary retention problem, consider whether the patient has cataracts before you prescribe. That's because the use of alpha blockers -- especially tamsulosin, marketed as Flomax -- is associated with an eye condition that makes cataract surgery more difficult, even in patients who no longer use these drugs. So says a July 2 educational update statement from the American Society of Cataract and Refractive Surgery, or ASCRS, and the American Academy of Ophthalmology, or AAO.
Photo showing intraoperative floppy iris syndrome
This surgical image shows iris billowing, progressive miosis and iris prolapse to the incision.
The two ophthalmology organizations are reaching out to primary care physicians to highlight the association between alpha blockers and a condition called intraoperative floppy iris syndrome, or IFIS, which can complicate cataract surgery.

"When we do cataract surgery, the wider the pupil dilates, the better we see the internal anatomy," says David Chang, M.D., chair of the ASCRS Cataract Clinical Committee and clinical professor of ophthalmology at the University of California, San Francisco. "IFIS causes poor preoperative pupil dilation; billowing and prolapse of the iris, which is floppy instead of rigid; and progressive constriction of the pupil during surgery. Once the pupil constricts intraoperatively, the risk of complications such as tearing the lens capsule or the iris rises significantly.

"The most common way of dealing with poor preoperative pupil dilation used to involve stretching the pupil with instruments -- but because of the floppy iris, pupil stretching backfires with IFIS and makes the situation worse."

Chang and a colleague first reported on IFIS and its association with tamsulosin in 2005. Since then, IFIS has been reported with other alpha blockers, but there appears to be growing evidence that IFIS is either more severe or more common with tamsulosin use, Chang says. The ASCRS-AAO statement says that in one prospective study, 90 percent of 167 eyes in patients taking tamsulosin exhibited some degree of IFIS during cataract surgery.

WHAT THE ASCRS-AAO STATEMENT SUGGESTS

"In a patient with a known diagnosis of cataract, prescribing physicians may wish to consider involving the patient's cataract surgeon prior to initiating nonemergent, chronic tamsulosin or alpha blocker treatment. Options might include an eye exam or having either the patient or the prescribing M.D. communicate with the cataract surgeon. Patients should also be encouraged to report any prior or current history of alpha-1 antagonist use to their ophthalmic surgeon prior to undergoing any eye surgery."
Tamsulosin is selective for the alpha-1A receptor subtype, which is predominant in the prostate, says Chang; the same alpha-1 subtype also is predominant in the iris.

The ASCRS-AAO statement includes highlights of a 2008 online survey ASCRS conducted to learn about members' clinical experience with IFIS. According to the statement, 95 percent of the nearly 1,000 respondents reported cataract surgery was more difficult in patients who were taking or had taken tamsulosin, and 77 percent said there was increased risk in patients taking tamsulosin compared with patients who were not taking the drug. Fifty-nine percent of respondents would recommend an ophthalmic evaluation for patients with a history of cataracts or decreased vision before initiating treatment with tamsulosin. Nearly two-thirds of respondents said they would avoid taking the drug if they themselves had a cataract or would have their cataract removed before starting the drug. Complete survey results appear in aspecial report in the July issue of theJournal of Cataract and Refractive Surgery.

"We're not presenting the member survey as a level I scientific study," Chang says, "but it does provide a snapshot of cataract surgeons' clinical experience with IFIS and points to their diversity of opinions and experiences with a variety of surgical problems that alpha blockers cause."

For patients with cataracts who are already taking alpha blockers for a health condition, "there's no evidence that switching or stopping the drug would be helpful," says Chang. "Interestingly, IFIS can occur one to two years after tamsulosin has been stopped. Cataract surgery can still be done with a good prognosis, but it's important for the surgeon to know about current or past alpha blocker use. The surgeon then can be prepared to deal with IFIS by using one of several alternative small pupil management strategies."

What about patients with cataracts who aren't taking alpha blockers but who may need to start them? "If the cataracts are to the point where surgery might be an option, we are asking the prescribing physician to consider involving the cataract surgeon before the decision is made to start an alpha blocker. The eye surgeon can assess not only how advanced the cataract is, but also how much risk an alpha blocker might add, particularly in light of other comorbidities. There's lots of variability in how complicated different cataract surgeries might be, depending on density of the lens and other individual risk factors," Chang says.

"Ophthalmologists truly respect how many different things a family physician has to juggle in managing the patient's medical problem list, and we don't want to arbitrarily increase that burden unnecessarily," Chang adds. "Ophthalmologists are ready and willing to take on the process of educating cataract patients about IFIS. We'd welcome the opportunity to be a resource for family physicians and their patients on this issue."



Tuesday, October 11, 2011

Even High-But-Normal Blood Pressure Elevates Stroke Risk, Medical News Today, 29 Sep. 2011

People with prehypertension have a 55 percent higher risk of experiencing a future stroke than people without prehypertension, report researchers at the University of California, San Diego School of Medicine in a new meta-analysis of scientific literature published in the September 28 online issue of the journal Neurology.

Prehypertension is clinical category created by experts in 2003 to describe patients whose blood pressure was elevated, but still considered within normal range.Hypertension or abnormally high blood pressure is a major risk factor for cardiovascular disease and strokes, but much less is known about the health threat posed of prehypertension, which is defined by a systolic pressure reading between 120 and 139 mmHg (the top number) and a diastolic reading between 80 and 89 mm Hg (the bottom number)

"The experts reasoned that, generally speaking, the higher the blood pressure, the greater the risk of death and disease, possibly starting from within the normal blood range," said Bruce Ovbiagele, MD, professor of neurosciences at UC San Diego School of Medicine and senior author of the study.

However, Ovbiagele said, conclusive evidence was lacking, "so we decided to compile all the published studies in the scientific literature to date, and using statistical techniques find out if there is indeed a higher risk of future stroke in people with prehypertension, the extent of that risk, and whether particular characteristics were associated with higher stroke risk."

The researchers identified 12 relevant prospective cohort studies of prehypertension. All of the studies were derived from the general population. Four were from the United States, five from Japan, two from China and one from India. Combined, the studies involved more than 518,000 participants and covered periods ranging from 2.7 years to 32 years, with stroke occurrences documented. The prevalence of prehypertension in the studies ranged from 25 to 46 percent. In the United States, it's estimated roughly one-third of adults have prehypertension.

"Overall, people who had prehypertension (in the studies) were at a 55 percent higher risk of experiencing a future stroke than people without prehypertension," said Ovbiagele. "This result held regardless of sex, race-ethnicity, blood pressure type (systolic or diastolic) or the type of stroke (ischemic or hemorrhagic)."

The health risk was measurably greater for those whose blood pressure levels were at the high end of the "normal" spectrum. "We found that those people who fell within the higher range of prehypertension were at 79 percent higher risk of experiencing a future stroke," Ovbiagele said.

The findings should add clarity to the perceived health risk of prehypertension, said Ovbiagele. "Prehypertension has been controversial since its inception, with occasional accusations that it would not be used to diagnose sick people, but rather it would label healthy people whose blood pressure was towards the upper reaches of normal as unhealthy, without any compelling reason for doing so. Others complained that the new designation would needlessly expose people to blood pressure-reduction drugs, all to the benefit of pharmaceutical companies."

Thomas Hemmen, MD, PhD, director of the UC San Diego Stroke Program and a neurologist at the UC San Diego Sulpizio Cardiovascular Center who was not involved in the study, described it as "ground-breaking."

"Over the years, the blood pressure range identified as increasing stroke and cardiovascular risk has been lowered," Hemmen said. "Now anything that's above 115 is thought to increase risk. But we need more tools for diagnosing prehypertension. We need to learn more so that we can adjust risk and develop therapies. Hopefully, this study will lead to more research."

Both Hemmen and Ovbiagele note little empirical evidence exists to show that taking blood pressure-reducing drugs can prevent future strokes. "There just haven't been any large studies," Hemmen said. On the other hand, both doctors say the new findings should encourage persons with high-but-normal blood pressure to change unhealthy behaviors.

"Young and middle-aged persons should check their blood pressure regularly. If they do fall into the higher range of prehypertension, they should take specific steps to modify their lifestyle, such as reducing salt intake and maintaining a normal weight," said Ovbiagele. "Modifying one's lifestyle is relatively safe and could potentially lower not just the risk of future strokes, but possibly other complications of prolonged elevation of blood pressure, including heart attacks,heart failure and kidney disease."



Original Article

아웃바운드 전략, 조선일보 2011.10.11


[내리막엔 감속해야 산다] [4] 아웃바운드 전략
중국 진출 36세 미용사, 연봉 8000만원으로 뛰어
동갑내기 국내 로펌 변호사, 겨우 취업… 연봉 7000만원
기업도 국내 안주한 곳은 해외 개척 기업에 뒤처져
독자적인 정보 채널 구축… 시장따라 맞춤 전략 필요

고졸 학력의 정이재(36·가명)씨는 직원 15명을 거느린 중국 칭다오 소재 고급 미용실의 원장님이다. 연봉은 8000만원 안팎. 공부 잘하는 친구들이 명문대에 입학할 때, 그는 L미용실 체인에 보조 미용사로 들어갔다. 6년 전 중국 근무를 자청한 것도 새 기회를 찾아서였다. 정씨는 "중국이 뜬다는 신문 기사를 읽고 무릎을 쳤다. 인구가 우리나라의 20배가 넘지 않나. 원장인 나까지 하루 20명 이상 손님을 받는다"고 했다. 이 미용실에서 머리를 한 번 손질하는 데는 한국 돈 70만원 이상을 내야 한다.

정씨와 동갑내기인 박수연(가명)씨는 국내 소형 로펌의 3년차 변호사다. 명문대 법대를 나와, 20대 후반에 사법시험에 합격했다. 석사과정까지 마친 탓에 사회 진출이 늦어 일자리를 찾느라 애를 먹었다. 현재 박씨의 연봉은 7000만원을 조금 넘는다. 그는 "변호사 숫자가 늘어 생계가 걱정"이라고 했다.

정이재씨와 박수연씨의 출발은 불공평했다. 고졸 학력의 미용 보조와 명문대 법대생. 70~80년대 국내에서만 벌어졌던 경쟁의 기준으론 따라잡기 힘든 간극이다. 그러나 성년 이후 두 사람의 선택은 소득 역전이라는 결과를 가져왔다. 원인은 두 사람이 '다른 속도'에서 경쟁했기 때문이다. 박수연씨는 감속(減速)하는 한국 경제에 머물렀던 반면, 정이재씨는 고속 성장하는 중국 시장으로 달려갔다.

◆'다른 속도'에 올라타라

국제통화기금(IMF)에 따르면 중국의 지난 6년간 국내총생산(GDP)은 평균 10.9% 성장한 반면, 한국은 3.8% 성장하는 데 그쳤다. 우리 경제는 과거에도 성장의 기회를 밖에서 찾아왔는데, 감속시대에는 더더욱 해외 진출이 절실해진다. 저성장 늪에 빠진 선진국보다 고성장하는 신흥국에 더 많은 기회가 있음은 물론이다.

 이미지를 클릭하시면 스냅샷으로 크게 볼 수 있습니다. / 조선닷컴
제빵업체 파리바게트 역시 다른 속도에 성공적으로 올라탄 사례다. 이미 중국 현지에 60개가 넘는 점포를 거느린 이 회사는 연내 100호점 개점을 목표로 삼고 있다. 직접 구운 빵을, 고급스런 카페 분위기 매장에서 판다는 현지화 전략이 중국 소비자들을 사로잡았다. 미용사 박씨나 파리바게트처럼 개인과 기업의 '아웃바운드(outbound)' 시도는 갈수록 늘고 있다. 국제기구에 진출한 한국인은 2007년 247명에서 2011년 올해 9월 말 현재 398명으로 불어났다. 2007년 299억7000만달러이던 국내 기업의 해외투자 규모는 2010년 325억3000만달러, 올 들어 6월 말까지 269억달러를 기록 중이다. 어떤 속도의 시장을 선택하느냐는 주가에도 반영된다. 베인앤컴퍼니에 따르면 농심, 오뚜기, 제일제당은 국내 시장에 안주한 탓에 주가수익비율(PER·주가를 주당순이익으로 나눈 것)이 10 내외에 머물러, 해외 진출에 성공한 아모레퍼시픽, 오리온 등 비교 기업군의 20에 비해 절반 가까이 저평가되고 있다.

◆'아웃바운드'는 생존을 위한 선택

아웃바운드 전략은 더 이상 소수의 엘리트 계층에만 해당되는 것이 아니다. 경제 주체 모두가 글로벌 경쟁에 노출된 상황에서 학력과 나이를 따지지 않고 필수적인 생존 전략 중 하나가 됐다. 리더십 전문가인 마셜 골드스미스 박사는 젊은이들에게 이렇게 충고했다. "우리는 인도와 중국의 저임금ㆍ고숙련 노동자들과 경쟁해야 한다. 가난하지만 대학을 졸업하고, 영어를 능숙하게 구사하며, 열심히 일하는 1억명의 젊은이들이다. 그들이 당신처럼 하루 종일 TV 보고, 인터넷 서핑이나 게임을 하면서 '세상이 썩었어'라고 불평할 것 같은가?"

베인앤컴퍼니는 해외에서 기회를 찾는 개인, 기업에 3가지를 충고한다.

①인터넷, 소셜미디어로 자기만의 '정보채널'을 만들어라

꼭 해외에 가서 외국인을 만나야 정보를 얻고, 사업 기회를 찾는 것이 아니다. 페이스북, 트위터를 통해 해외 '인맥'을 넓히고, 본인의 관심 분야 정보를 수집ㆍ축적해 파워블로거가 되라. 해외 진출을 위한 든든한 전진 기지가 될 것이다.

②시장에 따라 맞춤형 전략을 짜라

A시장에서 대박을 터뜨린 전략이 B시장에서는 쪽박이 될 수 있다. 시장이 10개라면 10개의 맞춤형 전략이 필요하다. 영국의 세계적 디자이너 폴 스미스의 모토는 '절대 넘겨짚지 마라(Never Assume)'이다. 그가 일본 시장에서 성공했던 것은 일본 시장을 넘겨짚지 않고 분석했고, 일본 문화와 음식을 사랑했기 때문이다.

③'코리안 프리미엄'을 활용하라

'코리아'라는 브랜드가 디스카운트가 아니라 프리미엄이 되는 시대이다. 외국어 못한다고 주눅 들지 말고 해외에서 코리아 프리미엄을 인정받을 수 있는 일을 찾아보라. 음식, 미용, 엔터테인먼트 같은 산업이 대표적이다. 

☞감속 시대

2008년 글로벌 위기가 덮친 이후 대한민국 경제 전반의 발전속도가 둔화된 현상을 말한다. 2001~2007년 연평균 경제성장률은 4.7%, 1인당 GDP 증가율은 9.8%를 기록했지만 2008년 이후 4년간(2008~2011년, 2011년은 추정치) 1인당 GDP 증가율은 평균 1.7%에 불과하다. 감속시대를 초래한 원인으로는 글로벌 금융위기, 급격한 노령화, 산업구조의 재편 등 세 가지 요인이 거론된다.

BAIN & COMPANY, 조선일보 공동기획


Copyright © ChosunBiz.com

Monday, December 27, 2010

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials, Lancet 2010

Lancet. 2010 Dec 6. [Epub ahead of print]
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW.

Stroke Prevention Research Unit, Department of Clinical Neurology, University of Oxford, Oxford, UK.
Abstract

BACKGROUND: Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of other cancers, particularly of the gastrointestinal tract, but proof in man is lacking. We studied deaths due to cancer during and after randomised trials of daily aspirin versus control done originally for prevention of vascular events.

METHODS: We used individual patient data from all randomised trials of daily aspirin versus no aspirin with mean duration of scheduled trial treatment of 4 years or longer to determine the effect of allocation to aspirin on risk of cancer death in relation to scheduled duration of trial treatment for gastrointestinal and non-gastrointestinal cancers. In three large UK trials, long-term post-trial follow-up of individual patients was obtained from death certificates and cancer registries.

RESULTS: In eight eligible trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled odds ratio [OR] 0·79, 95% CI 0·68-0·92, p=0·003). On analysis of individual patient data, which were available from seven trials (23 535 patients, 657 cancer deaths), benefit was apparent only after 5 years' follow-up (all cancers, hazard ratio [HR] 0·66, 0·50-0·87; gastrointestinal cancers, 0·46, 0·27-0·77; both p=0·003). The 20-year risk of cancer death (1634 deaths in 12 659 patients in three trials) remained lower in the aspirin groups than in the control groups (all solid cancers, HR 0·80, 0·72-0·88, p<0·0001; gastrointestinal cancers, 0·65, 0·54-0·78, p<0·0001), and benefit increased (interaction p=0·01) with scheduled duration of trial treatment (≥7·5 years: all solid cancers, 0·69, 0·54-0·88, p=0·003; gastrointestinal cancers, 0·41, 0·26-0·66, p=0·0001). The latent period before an effect on deaths was about 5 years for oesophageal, pancreatic, brain, and lung cancer, but was more delayed for stomach, colorectal, and prostate cancer. For lung and oesophageal cancer, benefit was confined to adenocarcinomas, and the overall effect on 20-year risk of cancer death was greatest for adenocarcinomas (HR 0·66, 0·56-0·77, p<0·0001). Benefit was unrelated to aspirin dose (75 mg upwards), sex, or smoking, but increased with age-the absolute reduction in 20-year risk of cancer death reaching 7·08% (2·42-11·74) at age 65 years and older.

INTERPRETATION: Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention. FUNDING: None. Copyright © 2010 Elsevier Ltd. All rights reserved. PMID: 21144578 [PubMed - as supplied by publisher]

Authorized only...

Wednesday, September 8, 2010

The New Science of Happiness

Of course, happiness is not a static state. Even the happiest of people—the cheeriest 10%—feel blue at times. And even the bluest have their moments of joy......


.....Diener has created one of the most basic and widely used tools, the Satisfaction with Life Scale. Though some scholars have questioned the validity of this simple, five-question survey, Diener has found that it squares well with other measures of happiness, such as impressions from friends and family, expression of positive emotion and low incidence of depression......


.....Just last month, a team led by Nobel-prizewinning psychologist Daniel Kahneman of Princeton University unveiled a new tool for sizing up happiness: the day-reconstruction method.....



.....There are numerous ways to do that, they argue. At the University of California at Riverside, psychologist Sonja Lyubomirsky is using grant money from the National Institutes of Health to study different kinds of happiness boosters. One is the gratitude journal—a diary in which subjects write down things for which they are thankful. She has found that taking the time to conscientiously count their blessings once a week significantly increased subjects' overall satisfaction with life over a period of six weeks, whereas a control group that did not keep journals had no such gain......



The New Science of Happiness

Monday, May 17, 2010

The science of happiness, By Mike Rudin Series producer, The Happiness Formula, 30 April 2006

Measuring happiness

Social scientists measure happiness simply by asking people how happy they are.

It is argued that what a person says about their own happiness tends to tally with what friends or even strangers might say about them if asked the same question.

Most people say they are fairly happy.


PDAs can be used to measure happiness levels during the day
The leading American psychologist Professor Ed Diener from the University of Illinois, told The Happiness Formula that the science of happiness is based on one straightforward idea:

"It may sound silly but we ask people 'How happy are you 1-7, 1-10?

"And the interesting thing is that produces real answers that are valid, they're not perfect but they're valid and they predict all sorts of real things in their lives."

One type of measurement even tries to record people's levels of happiness throughout the day wherever they are.

Ecological momentary assessment uses hand held computers.

The person being quizzed is bleeped and then taken through a questionnaire.

"The measures are not perfect yet I think they are in many ways as good as the measures economists use," said Professor Diener.

It is a remarkable claim. Simply by asking people, we have a measure of happiness that is as good as the economists' measure of poverty or growth.

And if true, governments could be judged by how happy they make us.

An adviser to the Prime Minister, David Halpern, told us that within the next 10 years the government would be measured against how happy it made everybody.
The science of happiness

Thursday, March 25, 2010

Does Anxiety Increase Risk Of Cardiovascular Disease?

Science Daily, Nov. 16, 2008


Ref)
Association between Anxiety and Factors of Coagulation and Fibrinolysis, 2008 Psychotherapy and Psychosomatics


Background: Psychological stress and anxiety have been shown to produce an activation of coagulation and fibrinolysis. Resulting hypercoagulability is a risk factor for cardiovascular diseases, and could therefore contribute to an increased
prevalence of coronary artery disease in anxiety patients. However, hemostasis function has not yet been studied in patients with clinically relevant anxiety disorders.

Methods: A group of anxiety patients (panic disorder with agoraphobia or social phobia) and a healthy control group (each n = 29) completed some questionnaires [SCL-K9 (a short form of the SCL-90-R), State Trait Anxiety Inventory,
ADS (general depression scale)], and had blood drawn after a 15-min rest period. To assess the reaction of the hemostatic system by global entities, sum scores were computed from parameters of coagulation and fibrinolysis (fibrinogen, FVII,
FVIII, vWF, F1 + 2, TAT, D -dimer, 2 -AP, PAP, tPA, PAI-1). Interfering variables, such as age, gender, alcohol consumption and smoking status, were controlled.

Results: Anxiety patients scored higher in a composite hemostatic score and a sum score of fibrinolysis in comparison to the control group, with a predominant activation of inhibitors in fibrinolysis. However, the psychological variable with the closest association to hemostasis was not trait anxiety, but self-perceived worry about blood drawing before blood sampling was performed.

Conclusions: The coagulation and fibrinolysis system is activated in the direction of a hypercoagulable state in patients with severe phobic anxiety, triggered by
fear of blood drawing. This could be one mediating factor for the increased risk of cardiovascular diseases in this population. Acute situational phobic anxiety should be monitored closely when studying the association between anxiety and
hemostasis.

Authorized only

Wednesday, March 10, 2010

WHO | Obesity and overweight, 2005

Overweight and obesity lead to serious health consequences. Risk increases progressively as BMI increases. Raised body mass index is a major risk factor for chronic diseases such as:

•Cardiovascular disease (mainly heart disease and stroke) - already the world's number one cause of death, killing 17 million people each year.
•Diabetes – which has rapidly become a global epidemic. WHO projects that diabetes deaths will increase by more than 50% worldwide in the next 10 years.
•Musculoskeletal disorders – especially osteoarthritis.
•Some cancers (endometrial, breast, and colon).
Childhood obesity is associated with a higher chance of premature death and disability in adulthood.

WHO | Obesity and overweight

Friday, February 19, 2010

Genetic risk scores don’t predict CVD, Feb. 2010 The Doctor's Channel

....Contrary to expectations, individual genetic markers don’t add up to a genetic risk score that’s any better than traditional risk factors for predicting cardiovascular disease, researchers are reporting....

Genetic risk scores don’t predict CVD, Feb. 2010 The Doctor's Channel

USPSTF Updates Screening Recs for Childhood, Adolescent Obesity, Feb. 2010 AAFP

New recommendations from the U.S. Preventive Services Task Force, or USPSTF, regarding screening for childhood and adolescent obesity call for moderate- to high-intensity interventions for obese patients.

USPSTF Updates Screening Recs for Childhood, Adolescent Obesity, Feb. 2010 AAFP